BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9863398)

  • 1. [Modern aspects of antiemetic therapy].
    Aleksandrović J; Dagović A; Jeremić B
    Srp Arh Celok Lek; 1998; 126(7-8):295-303. PubMed ID: 9863398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of antiemetic drugs.
    Jordan K; Schmoll HJ; Aapro MS
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granisetron: an update on its clinical use in the management of nausea and vomiting.
    Aapro M
    Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of drug-induced nausea and vomiting].
    Herrstedt J; Dombernowsky P
    Ugeskr Laeger; 1994 Jan; 156(4):453-60. PubMed ID: 8140660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE
    J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nausea and vomiting].
    Fujii M
    Nihon Rinsho; 2003 Jun; 61(6):954-8. PubMed ID: 12806942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.